Impressive data for another immuno-oncology / tyrosine kinase inhibitor (TKI) combo add up to yet more competition in the first-line kidney cancer setting.
Exelixis (Nasdaq: EXEL) and Bristol Myers Squibb (NYSE: BMY) outlined detailed results for a combination of Cabometyx (cabozantinib) and Opdivo (nivolumab), during a Presidential Symposium of the European Society for Medical Oncology (ESMO) annual congress.
Ahead of the presentation, Exelixis chief executive Michael Morrissey tells The Pharma Letter they were: "Great results,” and: “Really wonderful data.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze